Indication
Platinum-Resistant Ovarian Carcinoma
32 clinical trials
41 products
11 drugs
Clinical trial
Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-12-15
Product
PRGN-3005Clinical trial
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Product
ZEN-3694Product
IpilimumabClinical trial
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial CancerStatus: Recruiting, Estimated PCD: 2026-04-30
Product
TuvusertibClinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic CancersStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
T-VECClinical trial
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-30
Product
AldesleukinDrug
MelphalanProduct
NivolumabClinical trial
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AbemaciclibProduct
OlaparibClinical trial
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-09
Drug
AtezolizumabClinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor TherapyStatus: Withdrawn, Estimated PCD: 2023-03-17
Product
CopanlisibClinical trial
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersStatus: Recruiting, Estimated PCD: 2026-06-01
Product
CobimetinibProduct
PelcitoclaxClinical trial
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
PaclitaxelProduct
TopotecanClinical trial
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2027-03-17
Drug
cyclophosphamideDrug
fludarabineDrug
GemcitabineClinical trial
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-15
Product
DurvalumabProduct
TremelimumabClinical trial
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
FludarabineProduct
Interleukin-2Clinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AbraxaneClinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Product
CediranibDrug
AN0025Clinical trial
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Product
BatiraxceptDrug
TiragolumabClinical trial
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Product
AtovaquoneClinical trial
Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
LenvatinibClinical trial
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Product
GuadecitabineProduct
Poly ICLCDrug
mFOLFOX6Clinical trial
Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerStatus: Recruiting, Estimated PCD: 2025-02-15
Product
Pegylated SN-38 ConjugateClinical trial
Phase I/II Trial of Niraparib/Selenium Combination Treatment in Patients With BRCA1/2-Wild Type Recurrent Platinum-Resistant Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2026-11-27
Clinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
ElimusertibClinical trial
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-21
Product
Anetumab RavtansineClinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-02-09
Product
TolinapantClinical trial
A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-04-05
Clinical trial
A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2020-07-29
Drug
olaparibProduct
OnalespibClinical trial
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-12-30
Clinical trial
Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2025-05-28
Product
Akt/ERK Inhibitor ONC201Clinical trial
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Ziv-AfliberceptClinical trial
Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-09-01
Product
Bendamustine